|Written by GSCR Staff|
|Wednesday, 05 December 2012 08:45|
Good Morning! After a steady decline to a rock bottom of $2.09 in the fall of 2011, Albany Molecular Research (NASD – AMRI), reached a 52 week-high of $5.14 as the bio-tech sector ended the day yesterday up slightly.
Albany Molecular Research offers a wide variety of services from drug discovery and development to manufacturing. Additionally, the Company has several initial phases of pipeline products for which they are seeking partnership, including cancer treatments to obesity reduction products.
Since the stock bottomed in August of 2011, the Company has entered into several agreements made key management changes, and restructured where appropriate measures where necessary. AMRI reported excellent 3Q12 results highlighted by an 11% increase in revenue from the third quarter of 2011, an increase in the number of revenue streams including a 45% increase in royalty earnings from the third quarter of 2011, and an increase on guidance from royalty and EPS earnings for 2012.
With all the factors listed above, we see the stock going to the $6.00 mark in the near term.
Cornerstone Therapeutics Inc. (NASDAQ – CRTX - $5.15) is a niche pharmaceutical drug company specializing in hospital, respiratory, and other specialty drug markets. The company just had a slam dunk for third quarter earnings with an increase of 49% on revenues and 66% increase on net income from the third quarter 2011. A major part of this story is the completion of the integration of the EKR Therapeutic acquisition ahead of schedule bringing in $8 million in synergies.
The stock hit a 52-week high of $7.70 on July 31, and had a steady decline with some bad news on a new heart drug, lixivaptan, with a negative opinion from the FDA on September 14. The stock took a subsequent plunge to $5.06. We believe that all of the ‘bad news’ is already reflected in the stock price and that will not impact the valuation of the current successful and profitable business lines. We look for the stock to reach $7.00.
This Market Monitor blog was prepared for informational purposes only. Goldman Small Cap Research, (a division of Two Triangle Consulting Group, LLC) produces research via two formats: Goldman Select Research, which typically highlights small cap companies, and Goldman Opportunity Research, which features micro cap companies in a sponsored research format. Thus, the Select product reflects the Firm’s internally generated stock ideas while the Opportunity product reflects sponsored research reports.
It is important to note that while we may track performance separately, we utilize the same coverage criteria in determining coverage of all stocks in both research formats. Please view the company’s individual disclosures for each engagement, which can be found in each company-specific report. All information contained in this blog, newsletter and in our reports were provided by the Companies or generated from our own due diligence. Our analysts are responsible only to the public, and are paid in advance to eliminate pecuniary interests, retain editorial control, and ensure independence. Analysts are compensated on a per report basis and not on the basis of his/her recommendations.
The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy. Goldman Small Cap Research did not make an independent investigation or inquiry as to the accuracy of any information provided by the Company, or other firms. Goldman Small Cap Research relied solely upon information provided by the Company through its filings, press releases, presentations, and through its own internal due diligence for accuracy and completeness. Such information and the opinions expressed are subject to change without notice. A Goldman Small Cap Research blog, report, note, or newsletter is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed.
This blog does not take into account the investment objectives, financial situation, or particular needs of any particular person. This blog does not provide all information material to an investor’s decision about whether or not to make any investment. Any discussion of risks in this presentation is not a disclosure of all risks or a complete discussion of the risks mentioned. Neither Goldman Small Cap Research, nor its parent, is registered as a securities broker-dealer or an investment adviser with FINRA or with any state securities regulatory authority.
ALL INFORMATION IN THIS BLOG, REPORT OR NEWSLETTER IS PROVIDED “AS IS” WITHOUT WARRANTIES, EXPRESSED OR IMPLIED, OR REPRESENTATIONS OF ANY KIND. TO THE FULLEST EXTENT PERMISSIBLE UNDER APPLICABLE LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE FOR THE QUALITY, ACCURACY, COMPLETENESS, RELIABILITY OR TIMELINESS OF THIS INFORMATION, OR FOR ANY DIRECT, INDIRECT, CONSEQUENTIAL, INCIDENTAL, SPECIAL OR PUNITIVE DAMAGES THAT MAY ARISE OUT OF THE USE OF THIS INFORMATION BY YOU OR ANYONE ELSE (INCLUDING, BUT NOT LIMITED TO, LOST PROFITS, LOSS OF OPPORTUNITIES, TRADING LOSSES, AND DAMAGES THAT MAY RESULT FROM ANY INACCURACY OR INCOMPLETENESS OF THIS INFORMATION). TO THE FULLEST EXTENT PERMITTED BY LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE TO YOU OR ANYONE ELSE UNDER ANY TORT, CONTRACT, NEGLIGENCE, STRICT LIABILITY, PRODUCTS LIABILITY, OR OTHER THEORY WITH RESPECT TO THIS PRESENTATION OF INFORMATION.
For more information, visit our Disclaimer: www.goldmanresearch.com